Interferonbeta抗体;Interferonbeta Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of Interferon beta expression in HeLa cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

Interferon-beta (IFN-β) antibodies are primarily discussed in two contexts: as therapeutic agents and as immune responses to IFN-β therapies. IFN-β, a type I interferon, is a naturally occurring cytokine with antiviral and immunomodulatory properties. It is widely used to treat relapsing-remitting multiple sclerosis (MS) by reducing inflammation and modulating immune activity.

In the therapeutic context, monoclonal antibodies targeting IFN-β are not commonly used clinically. However, neutralizing antibodies (NAbs) against IFN-β represent a significant concern in MS treatment. Approximately 20-40% of patients receiving IFN-β therapies (e.g., IFN-β1a/1b) develop NAbs within 6-24 months of treatment. These antibodies can bind to IFN-β, reducing its bioavailability and therapeutic efficacy, potentially leading to diminished clinical benefits and increased relapse rates. NAb testing is recommended for patients showing reduced drug response.

Research on IFN-β antibodies also explores their role in autoimmune conditions. Some studies suggest naturally occurring anti-IFN-β antibodies may influence disease progression in MS or viral infections. Additionally, engineered anti-IFN-β antibodies are investigated as research tools to study interferon signaling pathways or potential therapies for interferon-mediated pathologies.

The clinical management of IFN-β antibody development remains challenging, balancing therapeutic efficacy with immunogenicity concerns. Current efforts focus on improving IFN-β formulations, developing antibody detection assays, and understanding genetic factors influencing NAb production.